From Bench to Bedside: Ensuring Adoption of Novel Clinical Biomarkers in Bladder Cancer
- Understanding drivers and barriers for the adoption of biomarkers in a new disease area
- Sharing J&Js approach to market shaping through agility and partnerships
- Future perspectives on how to manage adoption in the evolving landscape and new CDx modalities, such as AI